PERRIGO Co plc 2026: Revenue $1.02B, EPS $0.53— 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Perrigo Co plc reported Q2 2026 results with net sales of $1.02B, a 3.2% YoY decline, and diluted EPS of $0.53, marking a swing to positive net income of $74.5M from a loss in the prior year. Revenue was impacted by soft consumption and lower inventory, though store-brand strength and brand momentum for Opill® and Compeed® provided support. The company completed workforce reductions and operational enhancements while reviewing its infant formula business.
PERRIGO Co plc reported results for the 2026 quarter with net sales of $1.02B and diluted earnings per share of $0.53, marking a revenue decline versus the prior year and a swing to positive net income of $74.5M — 10-Q Summary.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $1.02B | $1.06B | (3.2%) |
| Net income² | $74.5M | ($8.4M) | 986.9% |
| Diluted EPS³ | $0.53 | ($0.06) | 983.3% |
¹ Reported as “Net sales”. ² Reported as “Net income (loss)”. ³ Reported as “Diluted earnings (loss) per share”.
Business Highlights
- Revenue trend: Net sales declined roughly 3–5% year-to-date, driven by soft consumption and lower retailer inventory levels, primarily in Self Care.
- Channel & mix: Continued store-brand strength offset by lower seasonal cough/cold demand and the Dermacosmetics divestiture, which reduced sales mix.
- Brand momentum: Opill®, ellaOne® and Compeed® gained share; Infant Formula experienced contract shipment growth despite prior production challenges.
- Operations: Completed Supply Chain Reinvention and Project Energize targets and launched an Operational Enhancement program to reduce costs and cut roughly 7% of the workforce.
- Quality & regulatory: Completed infant formula plant resets, strengthened quality assurance protocols after FDA interactions, and initiated a strategic review of the infant formula business.
Original SEC Filing: PERRIGO Co plc [ PRGO ] - 10-Q - Aug. 05, 2026